DDInter676 DDInter1658
Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including,, and, for example.[A177271, F4498] Its efficacy is considered similar to other medications within the PPI class including,,,, and. Esomeprazole is the s-isomer of, which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as, without any significant differences between the two compounds _in vitro_. Esome
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Esomeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Esomeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Esomeprazole {u} (Compound) binds {v} (Gene) ATP4A
Esomeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
Esomeprazole {u} (Compound) palliates {v} (Disease) prostate cancer
Esomeprazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Esomeprazole {u} (Compound) downregulates {v} (Gene) TRAPPC3
Esomeprazole {u} (Compound) causes {v} (Side Effect) Muscle spasms
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Choline salicylate
Esomeprazole (Compound) resembles Lansoprazole (Compound)
Esomeprazole (Compound) resembles Omeprazole (Compound)
Esomeprazole (Compound) treats Barrett's esophagus (Disease)
Esomeprazole (Compound) binds ATP4A (Gene)
Esomeprazole (Compound) upregulates TIPARP (Gene)
Esomeprazole (Compound) palliates prostate cancer (Disease)
Esomeprazole (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Esomeprazole (Compound) downregulates TRAPPC3 (Gene)
Esomeprazole (Compound) causes Muscle spasms (Side Effect)
Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Choline salicylate